Cytomegalovirus (CMV) infection remains one of the most significant complications in
transplant medicine, particularly in patients undergoing allogeneic hematopoietic stem cell
transplantation (HSCT). For compounding pharmacies in France, the growing demand for
advanced antiviral solutions presents a timely opportunity—especially with the availability
of Letermovir, a next-generation antiviral agent that is reshaping CMV prophylaxis globally.
MedicaPharma now supplies GMP-grade Letermovir API to French pharmacies and
pharmaceutical manufacturers looking to expand their offerings to transplant centres,
immunocompromised populations, and clinical specialists. With its novel mechanism of
action and integration into international transplant protocols, Letermovir is a strategically
important molecule for forward-looking compounders operating in this complex therapeutic
area.
Download GMP-Certified API Product List
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations. Click here to download our complete API product list.
“Medicapharma’s products and services are exclusively available to licensed companies and professionals. We do not sell to individuals or private consumers.”
Get your requested raw materials quotation
Table of Contents
What Is Letermovir?
Letermovir is a selective antiviral developed specifically for the prevention of CMV infection
in adult HSCT recipients. Unlike traditional antivirals such as ganciclovir or valganciclovir,
which target viral DNA polymerase, Letermovir acts on the CMV terminase complex—a
vital component in viral DNA processing and packaging. This targeted mechanism inhibits
viral replication without affecting host cellular enzymes, offering greater specificity and
improved tolerability.
Approved by both the European Medicines Agency (EMA) and the U.S. FDA, Letermovir
has become a standard prophylactic agent in many transplant protocols worldwide. Its
relevance continues to grow as more transplant centres integrate it into first-line prevention
strategies, including those in France’s expanding network of university hospitals and
cancer institutes.
Get your requested raw materials quotation
The Role of Letermovir in the French Healthcare Landscape
France has one of the most advanced transplant care systems in Europe, with numerous
public and private centres offering allogeneic HSCT. CMV infection remains a leading
cause of post-transplant morbidity, often requiring intensive monitoring and treatment.
While traditional antivirals remain effective, their side effect profiles—including bone
marrow suppression and renal toxicity—can limit their use in vulnerable patients.
Letermovir presents a compelling alternative. Its improved safety profile allows for early,
sustained prophylaxis without negatively impacting hematopoiesis or renal function. For
French compounding pharmacies, Letermovir opens the door to supporting specialised
transplant units with a high-value molecule backed by strong clinical evidence and broad
regulatory acceptance across the EU.
Get your requested raw materials quotation
Clinical Advantages of Letermovir
Letermovir’s clinical benefits are well established in peer-reviewed trials. It significantly
reduces the incidence of CMV reactivation in seropositive HSCT recipients and enables
more effective CMV management without the use of hematotoxic agents. Its
pharmacokinetic properties also support flexible administration, with both oral and
intravenous formulations available.
For compounding pharmacies, this offers versatility. Letermovir can be formulated in
various dosage forms to accommodate patient-specific needs, such as for paediatric
patients, those unable to take oral medication, or cases requiring dose adjustments. This
adaptability makes it a valuable addition to hospital-based pharmacies and specialist
compounding facilities serving transplant populations.
MedicaPharma: GMP-Grade Letermovir for the French Market
MedicaPharma offers Letermovir API manufactured under GMP conditions and authorised
by the Dutch Ministry of Health. All products are supplied with complete technical and
regulatory documentation, ensuring full traceability and compliance with EMA and ANSM
(Agence nationale de sécurité du médicament et des produits de santé) standards.
Each batch includes:
• Certificate of Analysis (CoA)
• Material Safety Data Sheet (MSDS)
• Full batch traceability documentation
• Regulatory support for French and EU markets
Our team works with pharmaceutical partners across France to ensure timely delivery,
clear documentation, and responsive service—enabling consistent, compliant access to
Letermovir for both commercial production and specialised compounding.
Supporting France’s Leadership in Transplant Medicine
France is a leader in European transplant care, with highly specialised centres in cities
such as Paris, Lyon, Toulouse, and Marseille. These institutions are adopting more
personalised approaches to infection prevention in immunocompromised patients,
including off-label compounding where supported by clinical evidence.
Letermovir’s novel mechanism and tolerability make it an ideal candidate for integration
into these evolving protocols. Compounding pharmacies that offer Letermovir-based
formulations can support hospital units by improving access to timely, individualised
prophylaxis strategies, especially for patients with unique clinical profiles or intolerance to
standard treatments.
Request Letermovir from MedicaPharma
The demand for advanced CMV prophylaxis in France is growing. Hospitals and transplant
centres are increasingly turning to newer agents like Letermovir that align with modern
standards of care. For compounding pharmacies, this is a key opportunity to supply a
molecule with strong clinical backing and increasing clinical uptake across Europe.
MedicaPharma offers EU-GMP-certified Letermovir with complete documentation and
flexible supply options. Whether you are supporting a university hospital, a private clinic, or
a research-focused CDMO, we deliver the product quality and regulatory readiness you
need to integrate Letermovir into your operations.
Request a quote today to learn more about our Letermovir API and how MedicaPharma
can support your work in CMV prevention for the French healthcare market.
Get a Fast and Easy GMP-Certified API Quote
Focus on your compounding pharmacy business and let MedicaPharma take care of your APIs. Obtaining a quote is easy
